N
AVBP icon

Nuveen’s ArriVent BioPharma AVBP Stock Holding History

Nuveen’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
56,839
+3,221
+6% +$72.7K ﹤0.01% 2460
2025
Q4 		$1.08M Buy
53,618
+5,955
+12% +$124K ﹤0.01% 2581
2025
Q3 		$879K Hold
47,663
– – ﹤0.01% 2682
2025
Q2 		$1.04M Buy
47,663
+3,381
+8% +$70.2K ﹤0.01% 2585
2025
Q1 		$819K Hold
44,282
– – ﹤0.01% 2723
2024
Q4 		$1.18M Hold
44,282
– – ﹤0.01% 2641
2024
Q3 		$1.04M Buy
44,282
+26,712
+152% +$606K ﹤0.01% 2742
2024
Q2 		$326K Buy
17,570
+4,638
+36% +$82.7K ﹤0.01% 3129
2024
Q1 		$231K Buy
+12,932
New +$261K ﹤0.01% 3153

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nuveen's AVBP Position: Q1 2026 in Review

Nuveen increased its ArriVent BioPharma (AVBP) stake by 6% in Q1 2026, buying an estimated $72.7K and bringing the position to 56,839 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

Nuveen first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Nuveen held 56,839 shares of ArriVent BioPharma worth $1.31M as of Q1 2026.
  • Nuveen bought 3,221 ArriVent BioPharma shares in Q1 2026, an estimated $72.7K.
  • ArriVent BioPharma made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2460 holding.
  • Nuveen first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.